The clinical profile of benralizumab in the management of severe eosinophilic asthma

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 6, 2016, Pages 534-548

  Menzella, Francesco ^a   Lusuardi, Mirco ^b   Galeone, Carla ^a   Facciolongo, Nicola ^a   Zucchi, Luigi ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b PATHOLOGY UNIT   (Italy)

Author keywords

anti interleukin 5 monoclonal antibodies; benralizumab; biomarkers; cytokines; eosinophils; interleukin 5; severe asthma

Indexed keywords

BENRALIZUMAB; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 5; MEPOLIZUMAB; OMALIZUMAB; PLACEBO; RESLIZUMAB; TRANSCRIPTION FACTOR RUNX2; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; EOSINOPHILIC ASTHMA; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; TREATMENT PLANNING; ANIMAL; COMPARATIVE STUDY; EOSINOPHILIA; PATHOPHYSIOLOGY; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EOSINOPHILIA; HUMANS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 85000799154     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465816667659     Document Type: Review

References (83)

1. Al-Samri M., Benedetti A., Préfontaine D., Olivenstein R., Lemière C., Nair P., et al. (2010) Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples. J Allergy Clin Immunol 125: 1161-1163.
2. Bafadhel M., Davies L., Calverley P., Aaron S., Brightling C., Pavord I., (2014) Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 44: 789-791.
3. Baptista-dos-Reis R., Muniz V., Neves J., (2015) Multifaceted roles of cysteinyl leukotrienes in eliciting eosinophil granule protein secretion. Biomed Res Int 2015: 848762.
4. Barnett S., Nurmagambetov T., (2011) Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 127: 145-52.
5. Becchetti E., Bani D., Baroni T., (2011) In: Idelson-Gnocchi, (ed.), Istologia Umana. pp. 393-394. ISBN: 9788879475419.
6. Bel E., Wenzel S., Thompson P., Prazma C., Keene O., et al. SIRIUS Investigators (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371: 1189-1197.
7. Berek C., (2016) Eosinophils: important players in humoral immunity. Clin Exp Immunol 183: 57-64.
8. Bjermer C., Maspero J., Ciesielska M., O'Brien C., Zangrilli J., (2014) A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Resp J 44: 299.
9. Bousquet J., Rabe K., Humbert M., Chung K., Berger W., Fox H., et al. (2007) Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101: 1483-1492.
10. Brightling C., Bleecker E., Panettieri R. Jr, Bafadhel M., She D., Ward C., et al. (2014) Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2: 891-901.
11. Brown T., (2015) FDA panel backs mepolizumab for severe eosinophilic asthma. Medscape Medical News 11.
12. Busse W., Katial R., Gossage D., Sari S., Wang B., Kolbeck R., et al. (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125: 1237-1244.
13. Castro M., Mathur S., Hargreave F., Boulet L., Xie F., Young J., et al. (2011) Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184: 1125-1132.
14. Castro M., Wenzel S., Bleecker E., Pizzichini E., Kuna P., Busse W., et al. (2014) Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2: 879-890.
15. Clutterbuck E., Sanderson C., (1990) Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor. Blood 75: 1774-1779.
16. Curtis C., Ogbogu P., (2015) Evaluation and differential diagnosis of persistent marked eosinophilia. Immunol Allergy Clin North Am 35: 387-402.
17. Davila I., Valero A., Entrenas L., Valveny N., Herráez L., (2015) Relationship between serum total IgE and disease severity in patients with allergic asthma in Spain. J Investig Allergol Clin Immunol 25 (2): 120-127.
18. Djukanov R., (1996) Bronchoscopy as a research tool for the study of asthma pathogenesis and effects of antiasthma drugs. J Allergy Clin Immunol 98 (5 Pt 2): S41-5; discussion S64-S66.
19. Egan R., Athwal D., Bodmer M., Carter J., Chapman R., Chou C., et al. (1999) Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 49: 779-790.
20. European Network for Understanding Mechanisms of Severe Asthma (2003) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 22: 470-477.
21. Fabbri L., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. (2003) Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167: 418-424.
22. Fahy J., (2009) Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 6: 256-259.
23. Flood-Page P., Menzies-Gow A., Kay A., Robinson D., (2003) Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199-204.
24. Flood-Page P., Swenson C., Faiferman I., Flood-Page P., Swenson C., Faiferman I., et al. (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176: 1062-1071.
25. George L., Brightling C., (2016) Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis 7: 34-51.
26. Gevaert P., Lang-Loidolt D., Lackner A., et al. (2006) Nasal IL-5 levels deterthe response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118 (5): 1133-1141.
27. Global Asthma Report (2014) Global burden of disease due to asthma. Available at: http://www.globalasthmareport.org/burden/burden.php (. accessed 4 July 2016).
28. Gossage D., Geba G., Gillen A., (2010). A multiple ascending subcutaneous dose study of MEDI-563, A humanized anti-IL-5RA monoclonal antibody, in adult asthmatics (clinicaltrails.gov Identifier: NCT00783289). Annual Congress of the European Respiratory Society (ERS).
29. Grainge C., Thomas P., Mak J., Benton M., Lim T., Ko F., (2016) Year in review 2015: asthma and chronic obstructive pulmonary disease. Respirology 21: 765-775.
30. Haldar P., Pavord I., Shaw D., Berry M., Thomas M., Brightling C., et al. (2008) Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178: 218-224.
31. Hanania N., Wenzel S., Rosén K., Hsieh H., Mosesova S., Choy D., et al. (2013) Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 (8): 804-811.
32. Hart T., Cook R., Zia-Amirhosseini P., Minthorn E., Sellers T., Maleeff B., et al. (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 108: 250-257.
33. Hasegawa K., Stoll S., Ahn J., Bittner J., Camargo C. Jr, (2015) Prevalence of eosinophilia in hospitalized patients with asthma exacerbation. Respir Med 109: 1230-1232.
34. Holgate S., (2008) Pathogenesis of asthma. Clin Exp Allergy 38: 872-897.
35. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309-316.
36. Iida S., Misaka H., Inoue M., Shibata M., Nakano R., Yamane-Ohnuki N., et al. (2006) Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 12: 2879-2887.
37. Izuhara K., Conway S., Moore B., Matsumoto H., Holweg C., Matthews J., et al. (2016) Roles of periostin in respiratory disorders. Am J Respir Crit Care Med 193: 949-956.
38. Jatakanon A., Lim S., Kharitonov S., Chung K., Barnes P., (1998) Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 53: 91-95.
39. Jia G., Erickson R., Choy D., Mosesova S., Wu L., Solberg O., et al. (2012) Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 130: 647-654.
40. Kaczmarski R., Mufti G., (1991) The cytokine receptor superfamily. Blood Rev 5: 193-203.
41. Katz L., Gleich G., Hartley B., Yancey S., Ortega H., (2014) Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 11: 531-536.
42. Kips J., O'Connor B., Langley S., et al. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167: 1655-1659.
43. Klein Wolterink R., Kleinjan A., van Nimwegen M., Bergen I., de Bruijn M., Levani Y., et al. (2012) Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 42: 1106-1116.
44. Kolbeck R., Kozhich A., Koike M., Peng L., Andersson C., Damschroder M., et al. (2010) MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125: 1344-1353.
45. Kouro T., Takatsu K., (2009) IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 21: 1303-1309.
46. Laviolette M., Gossage D., Gauvreau G., Leigh R., Olivenstein R., Katial R, et al. (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132: 1086-1096.
47. Leckie M., ten Brinke A., Khan J., Diamant Z., O'Connor B., Walls C., et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148.
48. Lommatzsch S., Martin R., Good J. Jr, (2013) Importance of fiberoptic bronchoscopy in identifying asthma phenotypes to direct personalized therapy. Curr Opin Pulm Med 19: 42-48.
49. Masoli M., Fabian D., Holt S., Beasley R., (2012) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59: 469-478.
50. McKinnon M., Bank M., Solari R., Robinson G., (1999) Interleukin-5 and the interleukin receptor: targets for drug discovery in asthma. In: Sanderson C., (ed.), Interleukin-5: From Molecule to Drug Target for Asthma. New York: Marcel Dekker, Inc., pp. 299-320.
51. Menzella F., Facciolongo N., Piro R., Formisano D., Roggeri A., Simonazzi A., et al. (2012) Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow up. Ther Adv Respir Dis 6: 87-95.
52. Menzella F., Zucchi L., Piro R., Galeone C., Castagnetti C., Facciolongo N., (2014) A budget impact analysis of bronchial thermoplasty for severe asthma in clinical practice. Adv Ther 31: 751-761.
53. Menzies-Gow A., Flood-Page P., Sehmi R., Burman J., Hamid Q., Robinson D., et al. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111: 714-719.
54. Nair P., Pizzichini M., Kjarsgaard M., Inman M., Efthimiadis A., Pizzichini E., et al. (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360: 985-993.
55. Normansell R., Walker S., Milan S., Walters E., Nair P., (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 1: CD003559.
56. Nowak R., Parker J., Silverman R., Rowe B., Smithline H., Khan F., et al. (2015) A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med 33: 14-20.
57. Ortega H., Liu M., Pavord I., Brusselle G., FitzGerald J., Chetta A., et al. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198-1207.
58. Park H., Kim M., Imai N., Nakanishi T., Adachi M., Ohta K., et al. (2016) A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol 169: 135-145.
59. Pavord I., Korn S., Howarth P., Bleecker E., Buhl R., Keene O., (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659.
60. Pepe C., Foley S., Shannon J., Lemiere C., Olivenstein R., Ernst P., et al. (2005) Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 116: 544-549.
61. Pham T., Damera G., Newbold P., Ranade K., (2016) Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med 111: 21-29.
62. Prazma C., Wenzel S., Barnes N., Douglass J., Hartley B., Ortega H., (2014) Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Thorax 69 (12): 1141-1142.
63. Rothenberg M., Hogan S., (2006) The eosinophil. Ann Rev Immunol 24: 147-174.
64. Rothenberg M., Klion A., Roufosse F., Kahn J., Weller P., Simon H., et al. (2008) Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358: 1215-1228.
65. Saha S., Brightling C., (2006) Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 1: 39-47.
66. Sahid El-Radhi A., Hogg C., Bungre J., Bush A., Corrigan C,. (2000) Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child 83: 158-162.
67. Schleich F., Seidel L., Sele J., Manise M., Quaedvlieg V., Michils A., et al. (2010) Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 65: 1039-1044.
68. Simpson J., Scott R., Boyle M., Gibson P., (2006) Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 11: 54-61.
69. Sin D., Miravitlles M., Mannino D., Soriano J., Price D., Celli B., et al. (2016) What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 23. DOI: 10.1183/13993003.00436-2016.
70. Stein M., Villanueva J., Buckmeier B., Yamada Y., Filipovich A., Assa'ad A., et al. (2008) Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 121: 1473-1483.
71. Tai P., Sun L., Spry C., (1991) Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 85: 312-316.
72. Takagi M., Hara T., Ichihara M., Takatsu K., Miyajima A., (1995) Multi-colony stimulating activity of interleukin 5 (IL-5) on hematopoietic progenitors from transgenic mice that express IL-5 receptor alpha subunitconstitutively. J Exp Med 181: 889-899.
73. Tanaka H., Komai M., Nagao K., Ishizaki M., Kajiwara D., Takatsu K., et al. (2004) Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 31: 62-68.
74. Toba K., Koike T., Shibata A., Hashimoto S., Takahashi M., Masuko M., et al. (1999) Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry 35: 249-259.
75. Trivedi A., Pavord I., Castro M., (2016) Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. Lancet Respir Med 4: 585-592.
76. Valent P., (1994) The phenotype of human eosinophils, basophils, and mast cells. J Allergy Clin Immunol 94: 1177-1183.
77. Wagener A., de Nijs S., Lutter R., Sousa A., Weersink E., Bel E., et al. (2015) External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 70: 115-120.
78. Walsh G., (2013) Eosinophil apoptosis and clearance in asthma. J Cell Death 6: 17-25.
79. Watz H., Tetzlaff K., Wouters E., Kirsten A., Magnussen H., Rodriguez-Roisin R., et al. (2016) Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 4: 390-398.
80. Wells T., Graber P., Proudfoot A., Arod C., Jordan S., Lambert M., et al. (1994) The three-dimensional structure of human interleukin-5 at 2.4-angstroms resolution: implication for the structures of other cytokines. Ann N Y Acad Sci 28 (725): 118-127.
81. Westerhof G., Korevaar D., Amelink M., de Nijs S., de Groot J., Wang J., et al. (2015) Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 46: 688-696.
82. Woodruff P., Modrek B., Choy D., Jia G., Abbas A., Ellwanger A., et al. (2009) T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180: 388-395.
83. Zia-Amirhosseini P., Minthorn E., Benincosa L., Hart T., Hottenstein C., Tobia L., et al. (1999) Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291: 1060-1067.